Anxiety and patients: Perspectives on surveillance and adjuvant therapy in renal cell carcinoma.

被引：0
|
作者：
Battle, Dena
Hammers, Hans J.
Jonasch, Eric
Derweesh, Ithaar
George, Daniel J.
Bex, Axel
Ljungberg, Borje
Staehler, Michael D.
机构：
[1] KCCure, Alexandria, VA USA
[2] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Univ Calif San Diego, San Diego, CA 92103 USA
[5] Duke Univ, Durham, NC USA
[6] Netherlands Canc Inst, Amsterdam, Netherlands
[7] Umea Univ, Umea, Sweden
[8] Ludwig Maximilians Univ Munchen, Univ Hosp Munich Grosshadern, Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.4571
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4571
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Renal cell carcinoma. Drug therapy and prognostic models
    Reiter, M. A.
    Kurosch, M.
    Haferkamp, A.
    [J]. UROLOGE, 2015, 54 (05): : 735 - 748
  • [32] Active surveillance as a treatment option for metastatic or recurrent renal cell carcinoma.
    Park, Inkeun
    Lee, Jae-Lyun
    Ahn, Jin-Hee
    Jeong, In Gab
    Song, Cheryn
    Hong, Bum-Sik
    Hong, Jun Hyuk
    Kim, Choung-Soo
    Ahn, Hanjong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [33] Adjuvant therapy for patients with renal cell carcinoma following surgery: a focus on pembrolizumab
    Serzan, Michael
    Atkins, Michael B.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (06) : 565 - 574
  • [34] Adjuvant therapy for renal cell carcinoma: how many patients are actually eligible?
    Klier, J.
    Doehn, C.
    Eichenauer, R.
    Koenig, F.
    Schoenfelder, R.
    Schroeder, J.
    Hempel, E.
    Johannsen, M.
    Schroeder, J.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 78 - 78
  • [35] Combination therapy with nivolumab and tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma.
    Garmezy, Benjamin
    Zhang, Tian
    Laccetti, Andrew Leonard
    Economides, Minas P.
    Shah, Amishi Yogesh
    Tannir, Nizar M.
    Jonasch, Eric
    Msaouel, Pavlos
    Zurita, Amado J.
    Corn, Paul Gettys
    Venkatesan, Aradhana M.
    Brown, Landon Carter
    Kao, Chester
    Kinsey, Emily Noelle
    Harrison, Michael Roger
    Armstrong, Andrew J.
    George, Daniel J.
    Campbell, Matthew T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] Systemic therapy in patients with metastatic Xp11.2 translocation renal cell carcinoma.
    Yan, Xieqiao
    Li, Siming
    Chi, Zhihong
    Si, Lu
    Cui, Chuanliang
    Kong, Yan
    Zhou, Li
    Tang, Bixia
    Wu, Xiaowen
    Mao, Lili
    Wang, Xuan
    Lian, Bin
    Bai, Xue
    Dai, Jie
    Guo, Jun
    Sheng, Xinan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [37] Adjuvant therapy in renal cell carcinoma: Where are we?
    Eisen, Tim
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (07) : 492 - 498
  • [38] PATIENT PERCEPTIONS OF ADJUVANT THERAPY IN RENAL CELL CARCINOMA
    Staehler, Michael
    Rodler, Severin
    Vaishampayan, Ulka
    Ball, Mark
    Derweesh, Ithaar
    Msaouel, Pavlos
    Battle, Dena
    [J]. JOURNAL OF UROLOGY, 2023, 209 : E378 - E379
  • [39] Aftercare and adjuvant therapy for advanced renal cell carcinoma
    Lunger, Lukas
    Amiel, Thomas
    Gschwend, Juergen E.
    [J]. UROLOGE, 2022, 61 (05): : 495 - 499
  • [40] Prognostic factors in patients with advanced renal cell carcinoma.
    Pardo, P.
    Muriel, C.
    Esteban, E.
    Izquierdo, M.
    Astudillo, A.
    Martinez-Camblor, P.
    Corral, N.
    Crespo, G.
    Berros, J. P.
    Lacave, A. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345